Fresenius announced the launch of its denosumab biosimilars, Conexxence (denosumab) and Bomyntra (denosumab), in Europe. These biosimilars received approval from the European Commission in July 2025 for all… read more.
Eli Lilly and Company announced that the FDA approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to… read more.
Insmed announced that the European Commission has approved Brinsupri (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and… read more.
Roche announced that its first point-of-care test for the diagnosis of whooping cough (pertussis) and other Bordetella infections, has been granted FDA 510(k) clearance and Clinical Laboratory Improvement… read more.
Amgen and AstraZeneca announced that the FDA approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric… read more.
NICE (UK): Darolutamide with androgen deprivation therapy (ADT) can be used as an option to treat hormone-sensitive metastatic prostate cancer in adults, only if: i) docetaxel is not… read more.
Sandoz announced the European launch of Wyost (denosumab 120 mg) and Jubbonti (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved… read more.
GE HealthCare announced CE Mark for its next-generation Omni 128cm total body positron emission tomography / computed tomography (PET/CT) system, a major milestone in its mission to advance… read more.
Alvotech announced that the European Commission (EC) has approved AVT 03 as a biosimilar to Prolia and Xgeva (denosumab). AV T03 is approved in two presentations: as a… read more.
Lundbeck A/S (Lundbeck) announced that new pipeline data regarding bexicaserin (LP352), a novel investigational drug for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs), will… read more.
Arrowhead Pharmaceuticals, Inc. announced that the FDA has approved Redemplo (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with… read more.
UCB, a global biopharmaceutical company, today announced it will present 21 abstracts at the American Epilepsy Society (AES) Annual Meeting (December 5-9, 2025). Data include primary efficacy and… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
